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Alopecia areata is a complex genetic, immune-
mediated disease that targets anagen hair follicles.
The disease affects children and adults and is char-
acterized by round or oval patches of hair loss, loss of
all scalp hair (alopecia totalis), body hair (alopecia
universalis), or ophiasis pattern hair loss. Patients
may also present with patchy loss in multiple hair-
bearing areas. Commonly associated diseases include
asthma, allergic rhinitis, atopic dermatitis, thyroid dis-
ease, and automimmune diseases, such as thyroiditis
and vitiligo. Nail abnormalities may precede, follow, or
occur concurrently with hair loss activity. Alopecia
areata has no known age, race, or ethnic preponder-
ance and in contrast to other autoimmune diseases
such as thyroiditis or lupus, the hair follicle does not
usually sustain permanent injury and maintains its
potential to regrow hair. It is estimated that alopecia
areata affects between six and seven million indivi-
duals in the United States. Genes, the immune and
nervous systems have all been implicated in the
pathogenesis of alopecia areata. Although many treat-
ments are available, there is still no cure. Bolstered by
new scientific and translational opportunities from
recently published genome-wide association studies,
an ambitious treatment development program has
recently been initiated by the National Alopecia Areata
Foundation.
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INTRODUCTION: ETIOLOGY OF ALOPECIA AREATA
Immunology
A hallmark of active alopecia areata is the presence of
peribulbar lymphocytes around the bulb region of anagen
hair follicles (Alkhalifah et al., 2010; Gilhar et al., 1998,
2012). Killer CD8þ T cells in this infiltrate are thought
to be attracted to this region by the expression of the natural
killer group 2D (NKG2D) ligand. Recent studies have
also demonstrated the expression of cytomegalovirus UL16-
binding protein in lesional scalp of patients with active
disease, providing evidence for the involvement of both
innate and acquired immunity in the pathogenesis of
alopecia areata (Ito et al., 2008, 2012; Petukhova et al.,
2010; Forstbaurer et al., 2012) Additional mechanisms include
the loss of immune privilege in the hair follicle. (Kang et al.,
2010)
Transplantation studies in severe-combined immunodefi-
cient mice have shown T cell immunity is directly involved in
the disease. In recent experiments, injections of peripheral
blood mononuclear cells enriched for NKG2Dþ cells and
activated by phytohemagglutinin/IL-2 from healthy individuals
into healthy human skin transplanted onto severe-combined
immunodeficient mice resulted in a hair loss pattern similar
to the human alopecia areata phenotype, including hair
follicle immune privilege collapse (Gilhar et al., 1998, 2012).
This model is believed to be the first functional evidence of
the concept that NKG2Dþ and/or CD56þ cells as well
as the NKG2D–stimulating ligands have key roles in alopecia
areata.
The nervous system
Many but not all patients describe stressful life events in
relationship to the onset and progression of alopecia areata.
Alterations in perifollicular innervation have been described
but to date a distinct role for neurogenic inflammation in
the pathogenesis of alopecia areata remains to be identified
(Peters et al., 2006; Cutter and Pittelkow, 2006). The
expression of the neuropeptide substance P (SP) and its
effects on immune cells in a C3H/HeJ mouse model for
alopecia areata have been examined and the number of SP–
immunoreactive nerve fibers in skin was found to be increased
in evolving alopecia areata. In contrast, in more advanced
stages of the disease, the number of SP–immunoreactive
nerves and SP protein levels in skin were found to be
decreased, and the SP–degrading enzyme neutral endopepti-
dase increased. These results suggest that SP, neutral endo-
peptidase, and NK-1R can serve as regulators in the molecular
signaling network modulating inflammatory response in auto-
immune hair loss such as alopecia areata. (Siebenhaar et al,
2007). Further support that a neuronal abnormality may be
present in alopecia areata comes from the observation that
both SP– and calcitonin gene–related peptide expression vary
in alopecia areata scalp eccrine glands (Hordinsky et al,
1995). The expression of neuropeptides and neuropeptide
receptors by nerves as well as immune cells provides
a link between the peripheral nervous system, the central
nervous system, and the skin immune system that deserves
further study.
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Genetics
Genetic complexity underlies the heterogeneity seen in
alopecia areata. For instance, the concordance rate among
identical twins is roughly 55%, not high enough to be
considered for dominant inheritance. Family-based studies in
the United States show that roughly a third of probands have a
biological relative with alopecia areata. Recurrence risks of
around 5–6% are estimated for the children of affected
individuals (Blaumeiser et al., 2006; Rodriguez et al., 2010).
In 2010, a genome-wide association study of 3,278 control
subjects and 1,054 well-characterized cases from the Alopecia
Areata Registry was published. This Registry was established
in 2001 with the goal of better understanding the causes of
alopecia areata as well as treatments. The results from well-
characterized Registry samples revealed eight genetic loci
contributing to alopecia areata such as the HLA region, the
UL16-binding protein gene cluster, cytotoxic T-lymphocyte
antigen 4 (CTLA4), interleukins (IL-2/IL-21, IL-2RA), and
several genes that control the differentiation and main-
tenance of regulatory T cells. These genomic regions were
also noted to be associated with other diseases such as
rheumatoid arthritis and celiac disease, other autoimmune
diseases with pre-existing treatments, making it possible to
consider using these treatments for alopecia areata (Duvic
et al., 2003; Petukhova et al., 2010). The key genes identified
in the 2010 genome-wide association study were corroborated
and additional genes identified in two subsequent genome-
wide studies (Petukhova et al., 2010; Forstbaurer et al., 2012;
Jagielska et al., 2012). Taken together, these three genome-
wide association studies show evidence for associations of
alopecia areata with genomic regions that have a role in the
immune system and/or hair follicle.
TREATMENT: CHALLENGES
There is currently no cure for alopecia areata and no
universally proven therapy that induces and sustains remission
(Delamere et al., 2008). Many therapies are available but there
continue to be very few published randomized controlled
clinical trials in alopecia areata. However, the application
of the Alopecia Areata Investigational Guidelines in clinical
studies has recently provided some standardization (Olsen
et al., 1999). Current treatment choices include a variety of
topical, intralesional, and systemic agents with the choice and
recommendation based on disease extent, duration, associated
medical conditions, and age of the patient.
TREATMENT: OPPORTUNITIES
In October 2010, a Translational Research Summit was
sponsored by the National Alopecia Areata Foundation and
held at Columbia University in New York City. The primary
goal of this meeting was to address how to improve and fast
track new treatments for alopecia areata in a coordinated,
efficient, safe, and scientifically sound manner. Findings from
the recent genetic studies have opened new avenues of
treatment exploration based on the underlying mechanisms
of alopecia areata and applying therapies already in trials or
approved for other autoimmune diseases (Hordinsky, 2011).
Trials are currently in progress or being initiated that take into
account what we have known about mechanisms common to
alopecia areata and other types of autoimmunity, T cell–
related mechanisms and the IL-15 pathway or pathways
downstream of the NKG2D receptor. In conjunction, other
potential therapies using novel devices or medications are also
in early clinical trial development to treat primarily patchy
alopecia areata. These include Bimatoprost, a prostamide F2
analog and Latanoprost, a prostaglandin F2a analog (Faghihi
et al., 2009; Ochoa et al., 2009) Finally, multicenter studies of
light therapy primarily with the excimer laser are in clinical
trial development (Al-Mutairi, 2009). Immune privilege-
protective drugs such as FK506 and/or antagonists of hair
follicle immune privilege collapse inducers remain to be
studied systematically to assess the effect of restoring a
collapsed immune privilege in alopecia areata patients.
There is also the potential of using medications that
moduate nerve and neuropeptide functions in alopecia
areata (Cutter and Pittelkow, 2006). The success of any of
these new approaches will be dependent on the design and
execution of outstanding clinical trials. The risks and benefits
of any new treatment will have to be carefully weighed,
particularly in children with alopecia areata.
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